近日,南京安吉生物宣布达成三款多肽新药(涵盖眼科与抗肿瘤治疗领域)的对外授权合作,协议结构中包括75万美元前期付款与525万美元首付款,高达4.53亿美元的潜在交易总额,再度印证了中国肽类创新药公司正在通过“License‑out”模式获得认可。与此同时,2025年以来,中国肽类创新药领域投融资活跃,公开资料显示至少发生20起融资事件,融资总额突破120亿元人民币,其中12起属于亿元级及以上,涵盖...
Source Link近日,南京安吉生物宣布达成三款多肽新药(涵盖眼科与抗肿瘤治疗领域)的对外授权合作,协议结构中包括75万美元前期付款与525万美元首付款,高达4.53亿美元的潜在交易总额,再度印证了中国肽类创新药公司正在通过“License‑out”模式获得认可。与此同时,2025年以来,中国肽类创新药领域投融资活跃,公开资料显示至少发生20起融资事件,融资总额突破120亿元人民币,其中12起属于亿元级及以上,涵盖...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.